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Welcome to this special issue of PPAR Research dedicated to
the “Genetic Variation of PPARs.” Since PPARs are nuclear
transcription factors regulating multiple genes involved in
energy production, glucose and lipid metabolism, polymor-
phisms in these receptors may inﬂuence the pathology of
numerous diseases including obesity, diabetes, atherosclero-
sis, inﬂammation and cancer.
The ﬁrst section of this special issue of PPAR Research
contains a series of four original research articles followed
by a review article examining the impact of PPAR gene
polymorphisms on various metabolic diseases. First is an
article by Deeb and Brunzell describing the impact of the
Gly482Ser polymorphism in the PPARG coactivator-1 alpha
(PPARGC1A) on weight gain in a diabetic population. A
second article by Dallongeville and coworkers examines the
association of PPARG gene polymorphisms with coronary
heart disease. Third, Wieczorek’s research group investigates
the consequences of polymorphisms in RXRB, PPARA,a n d
PPARG on Wegener’s Granulomatosis. Fourth, a study by
Ereqat et al. presents the results of an investigation of
the impact of the PPARG Pro12Ala polymorphism on the
metabolic and clinical characteristics in Palestinian type 2
diabetic patients. Finally this section ends with a review
by Weimin He on the inﬂuence of the PPARG Pro12Ala
polymorphism on insulin sensitivity, as well as other diseases
including cancer, polycystic ovary syndrome, Alzheimer
disease, and aging.
We are also pleased that this special issue contains two
articles that describe the functional eﬀects of the PPAR gene
polymorphisms. First, Rudkowska and co-researchers desc-
ribe the diﬀerences in transcriptional activation observed
in two allelic variants of PPARA (L162V) after omega-3
fatty acids treatment. Second, McCleelland et al. discern
the regulation of translational eﬃciency by disparate 5
UTRs of PPARG splice variants. These two articles lead to
a more complete understanding of the role and functional
repercussions of various PPAR gene polymorphisms in the
prevention and treatment of diseases.
In conclusion, while the inﬂuence and impact of PPAR
polymorphisms on health and disease is still mostly uncer-
tain, recent evidence suggests that these genetic variations
playanimportantroleintheinitiation/progressionofdisease
as well as in the eﬃcacy of speciﬁc treatments in particular
individuals/populations. We are fortunate to have received
contributions from such well-renowned experts in the ﬁeld,
and hope that you will ﬁnd that this special issue of
PPAR Research produces greater interest in this critical and
evolving ﬁeld of research.
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